CD274 and non-small cell lung carcinoma: (1) observed a PFS of 16.8 months versus 5.6 months and a heightened remission rate in the group treated with the combined modality of radiotherapy and anti-PD-L1 (Durvalumab) in comparison with radiotherapy and placebo in individuals with NSCLC.